C12N 2710/16662
By genetic engineering
Official title: by genetic engineering
C12N2710/16662 (By genetic engineering) appears on 55 US grants and 88 published applications in this corpus.
Search patents in C12N- Granted patents
- 55
- Published applications
- 88
- Assignees
- 49
- Inventors
- 129
- Latest grant
- 26 May 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2000 | 1 | 0 |
| 2001 | 3 | 0 |
| 2002 | 0 | 3 |
| 2003 | 1 | 3 |
| 2004 | 0 | 2 |
| 2005 | 0 | 1 |
| 2006 | 0 | 2 |
| 2007 | 0 | 1 |
| 2008 | 0 | 1 |
| 2009 | 0 | 3 |
| 2010 | 3 | 1 |
| 2011 | 1 | 5 |
| 2012 | 2 | 1 |
| 2013 | 2 | 5 |
| 2014 | 4 | 3 |
| 2015 | 0 | 2 |
| 2016 | 2 | 3 |
| 2017 | 3 | 8 |
| 2018 | 4 | 3 |
| 2019 | 6 | 5 |
| 2020 | 6 | 9 |
| 2021 | 2 | 3 |
| 2022 | 4 | 4 |
| 2023 | 2 | 7 |
| 2024 | 4 | 6 |
| 2025 | 4 | 4 |
| 2026 | 1 | 3 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Oncolytic virus compositions and methods for the treatment of cancer26 May 2026US 12,637,510 B2City of Hope
- Viral vectors for cancer therapy22 Jul 2025US 12,364,775 B2Krystal Biotech, Inc.
- High-transducing HSV vectors15 Apr 2025US 12,275,949 B2PeriphaGen, Inc.
- Replication-competent controlled alpha-herpesvirus vectors and uses therefore25 Mar 2025US 12,257,300 B2HSF Pharmaceuticals SA
- Engineered Herpes Simplex Virus-1 (HSV-1) vectors and uses thereof28 Jan 2025US 12,209,250 B2Massachusetts Institute of Technology
- Viral Vectors for Cancer Therapy30 Apr 2026US 2026/0115327 A1Krystal Biotech, Inc.
- Modified oncolytic herpes simplex virus (ohsv) and methods of use thereof9 Apr 2026US 2026/0097135 A1The General Hospital Corporation
- Transcriptional and translational dual regulated oncolytic herpes simplex virus vectors2 Apr 2026US 2026/0091069 A1Virogin Biotech Canada Ltd
- Method for treating glioma with ohsv22 Oct 2025US 2025/0302945 A1Binhui Biopharmaceutical Co., Ltd.
- Transcriptional and translational dual regulated oncolytic herpes simplex virus vectors22 May 2025US 2025/0161384 A1Virogin Biotech Canada Ltd
Most cited
By later US patents
- Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response41US 7,731,952 B2New York University · 2010
- Recombinant herpesvirus of turkeys comprising a foreign DNA inserted into a non-essential region of the herpesvirus of turkeys genome34US 6,121,043 ASyntro Corporation · 2000
- Viral vectors and their use in therapeutic methods31US 7,749,745 B2Georgetown University · 2010
- Methods of gene therapy using herpes viral vectors expressing GM-CSF20US 6,287,557 B1Cantab Pharmaceuticals Research Limited · 2001
- Viral vectors and their use in therapeutic methods20US 8,470,577 B2Catherex, Inc. · 2013